Remove Biopharma Remove FDA Remove Healthcare Remove Medical science
article thumbnail

Reducing real world data lag time for improved patient outcomes

Clarivate

In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. Biopharma companies are investing in the use of real world data (RWD) to accelerate innovation.

article thumbnail

15 Top Venture Capital for Biotech Companies

Medico Reach

Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 New Enterprise Associates.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

After FDA-approval comes the last critical mile of this journey: bringing the product to market. Successfully launching a new product is no easy feat in the life sciences industry; up to 66% of newly launched drugs fail to meet market expectations within their first year. sales, medical science liaisons, etc.).

article thumbnail

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Medgadget

Interestingly, due to FDA’s regulatory methodology, surgical robots have to be approved for specific indications by the agency. This year it is scheduled for May 16-18, 2023 in Tel Aviv, and topics range from medical robotics, to bio-convergence, to the impact of AI on biopharma.

article thumbnail

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Medgadget

The FDA looked at the data, saw it promising, and asked for a small feasibility study in the U.S. This will hopefully lead to an FDA approval for its first indication, after which Alpha TAU plans on expanding to other types of cancer and geographic regions such as Europe and Japan. The rest of the patients had partial responses.